Resurrect Bio Secures Additional £1.6m in Series A Funding to Advance Sustainable Crop Protection

London-based agricultural biotechnology firm Resurrect Bio Ltd has announced a further Series A funding round, securing £1.6m. The investment, filed on 27 April 2026 with an allotment date of 17 April 2026, will support the company's mission to develop disease-resistant crops using its proprietary gene editing platform and artificial intelligence.

Resurrect Bio is at the forefront of sustainable agriculture, focusing on resurrecting native plant immune genes to provide the seed industry with alternatives to chemical crop protection. This innovative approach enables staple crops such as soy, corn, wheat, potato, tomato, and spinach to naturally defend themselves against pathogens, reducing reliance on synthetic chemicals. The company's LinkedIn profile highlights its commitment to helping farmers increase food production, reduce agricultural land use, and mitigate climate change by fixing the immune systems of crop species.

Company Background and Growth Incorporated on 10 December 2021, Resurrect Bio has quickly established itself as a player in the plant biotech sector. The company's unique pipeline and platform are dedicated to discovering resistance genes in crops that have succumbed to pathogens and pests, then restoring these genes without introducing new DNA. This method aims to empower crops with their own defence mechanisms.

The company has shown consistent growth in its team. While its latest accounts reported 7 employees, the company's LinkedIn profile indicates a team of 15, suggesting recent expansion as it scales its research and development efforts. As a VC-backed startup, Resurrect Bio is focused on delivering practical solutions for farmers globally.

Funding Journey This latest £1.6m Series A round follows a significant £6.2m Series A raise on 26 January 2026, indicating strong investor confidence and a rapid pace of development for the company. Prior to these Series A rounds, Resurrect Bio successfully closed a seed funding round of £1.6m on 22 March 2023. Its initial funding, an early round of £125k, was secured on 15 February 2022 at a valuation of £600k, laying the groundwork for its subsequent growth. The valuation for the current £1.6m Series A round has not been disclosed.

UK AgriTech and Deep Tech Landscape Resurrect Bio's funding round occurs within a dynamic and growing UK AgriTech and Deep Tech landscape. The AgriTech sector in the United Kingdom has seen a substantial increase in investment in early 2026. Data indicates that AgriTech companies in the UK raised approximately £108m in equity funding across 8 rounds by April 2026, marking an impressive 833.13% rise compared to the £11.6m raised across 6 rounds in the same period of 2025. Over the last decade, the sector has attracted more than £1.39bn in total funding.

The broader UK AgriTech market is also projected for significant expansion, reaching an estimated £1,441.68m by 2034 from £557.2m in 2025, with a compound annual growth rate (CAGR) of 10.58% between 2026 and 2034. This growth is driven by advancements in precision farming, increasing demand for sustainable agricultural practices, and a heightened awareness of climate change.

Government initiatives are actively supporting this growth. In April 2026, around £50m in public and private investment was announced to accelerate the deployment of 12 innovative agri-tech tools, with £8m from government funding and £40m from private investment. Furthermore, an additional £5m government springboard funding round for 2026-27 was confirmed to attract further private investment and help high-potential agri-tech businesses scale up. Innovate UK also launched an £8m funding competition in March 2026 to support experimental development projects in agri-tech manufacturing.

Resurrect Bio's focus on gene editing aligns with key trends in the sector, particularly the increasing emphasis on precision breeding. The Genetic Technology (Precision Breeding) Regulations 2025, which came into effect in November 2025, have opened a clearer pathway for precision-bred plants in England, fostering a ramp-up in trials, registrations, and partnerships aimed at enhancing disease resistance and yield stability.

The biotechnology sector, which encompasses Resurrect Bio's work, is also experiencing a resurgence. UK biotech financing showed early signs of recovery in the first quarter of 2026, with total equity financing reaching £552m between January and March, an increase from £466m in Q4 2025. Venture capital played a crucial role, rising 17% quarter-on-quarter to £516m, and deal activity significantly increased to 25 VC transactions, up 67% year-on-year. The UK notably secured 57% of all European biotech venture capital during this quarter. The biotechnology industry's revenue is forecast to climb at a compound annual rate of 6.4% to £25.3bn through 2025-26, with agricultural applications broadening its appeal and economic value.

As a deep tech company, Resurrect Bio also benefits from a robust investment environment. Deep tech now accounts for 31% of all UK VC funding, a threefold increase over the last decade. 2025 was projected to be the second-strongest year on record for deep tech funding, with an estimated £5.92bn raised by year-end. Since 2019, UK deep tech startups have attracted approximately £34.96bn in venture capital, ranking third globally behind the US and China.

Resurrect Bio's continued ability to secure Series A funding underscores the growing investor appetite for innovative solutions in agricultural biotechnology, particularly those leveraging advanced technologies like gene editing and AI to address critical global challenges in food security and environmental sustainability.